Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement
Details
Publication Year 2023-10,Volume 24,Issue #10,Page e415-e423
Journal Title
Lancet Oncology
Publication Type
Review
Abstract
Anticancer agents can impair ovarian function, resulting in premature menopause and associated long-term health effects. Ovarian toxicity is not usually adequately assessed in trials of anticancer agents, leaving an important information gap for patients facing therapy choices. This American Society of Clinical Oncology (ASCO) statement provides information about the incorporation of ovarian toxicity measures in trial design. ASCO recommends: (1) measurement of ovarian toxicity in relevant clinical trials of anticancer agents that enrol post-pubertal, pre-menopausal patients; (2) collection of ovarian function measures at baseline and at 12-24 months after anticancer agent cessation, as a minimum, and later in line with the trial schedule; and (3) assessment of both clinical measures and biomarkers of ovarian function. ASCO recognises that routine measurement of ovarian toxicity and function in cancer clinical trials will add additional complexity and burden to trial resources but asserts that this issue is of such importance to patients that it cannot continue to be overlooked.
Publisher
Elsevier
Keywords
Female; Humans; United States; *Neoplasms/therapy; *Antineoplastic Agents/adverse effects; Ovary; Medical Oncology
Department(s)
Medical Oncology
PubMed ID
37797647
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-11-30 02:33:21
Last Modified: 2024-07-09 06:20:02

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙